Chardan Capital Reiterates “Buy” Rating for Immuneering (NASDAQ:IMRX)

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a report issued on Wednesday,Benzinga reports. They presently have a $13.00 target price on the stock.

Separately, Needham & Company LLC restated a “buy” rating and set a $15.00 price target on shares of Immuneering in a research note on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Immuneering presently has an average rating of “Moderate Buy” and an average price target of $12.80.

Immuneering Price Performance

Shares of IMRX opened at $2.11 on Wednesday. The firm has a fifty day moving average price of $2.22 and a 200 day moving average price of $1.62. The stock has a market cap of $65.52 million, a PE ratio of -1.07 and a beta of -0.40. Immuneering has a 1-year low of $1.00 and a 1-year high of $8.89.

Hedge Funds Weigh In On Immuneering

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. acquired a new stake in shares of Immuneering in the third quarter valued at about $25,000. Corsair Capital Management L.P. acquired a new position in shares of Immuneering during the 3rd quarter worth approximately $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Immuneering in the 2nd quarter valued at approximately $44,000. XTX Topco Ltd grew its holdings in Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after buying an additional 9,274 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Immuneering during the second quarter worth $67,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.